Rheumatic Heart Disease Treatment Market, Global Outlook and Forecast 2022-2028

April 2022 | 66 pages | ID: RD15C23278B3EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Rheumatic Heart Disease Treatment in Global, including the following market information:

Global Rheumatic Heart Disease Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Rheumatic Heart Disease Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Antibiotics Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Rheumatic Heart Disease Treatment include Eli Lilly, GlaxoSmithKline, Sanofi, Bristol-Myers Squibb, AstraZeneca, AbbVie, Merck, Roche and Pfizer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Rheumatic Heart Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Rheumatic Heart Disease Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Rheumatic Heart Disease Treatment Market Segment Percentages, by Type, 2021 (%)

• Antibiotics
• Anti-Inflammatory Treatment
• Anticonvulsant Medications

Global Rheumatic Heart Disease Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Rheumatic Heart Disease Treatment Market Segment Percentages, by Application, 2021 (%)

• Children
• Adult

Global Rheumatic Heart Disease Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Rheumatic Heart Disease Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Rheumatic Heart Disease Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Rheumatic Heart Disease Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Eli Lilly
• GlaxoSmithKline
• Sanofi
• Bristol-Myers Squibb
• AstraZeneca
• AbbVie
• Merck
• Roche
• Pfizer
• Boehringer Ingelheim Pharma
• Bayer
• Sun Pharm
• Amneal Pharmaceuticalsd

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Rheumatic Heart Disease Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Rheumatic Heart Disease Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL RHEUMATIC HEART DISEASE TREATMENT OVERALL MARKET SIZE

2.1 Global Rheumatic Heart Disease Treatment Market Size: 2021 VS 2028
2.2 Global Rheumatic Heart Disease Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Rheumatic Heart Disease Treatment Players in Global Market
3.2 Top Global Rheumatic Heart Disease Treatment Companies Ranked by Revenue
3.3 Global Rheumatic Heart Disease Treatment Revenue by Companies
3.4 Top 3 and Top 5 Rheumatic Heart Disease Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Rheumatic Heart Disease Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Rheumatic Heart Disease Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Rheumatic Heart Disease Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Rheumatic Heart Disease Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Rheumatic Heart Disease Treatment Market Size Markets, 2021 & 2028
  4.1.2 Antibiotics
  4.1.3 Anti-Inflammatory Treatment
  4.1.4 Anticonvulsant Medications
4.2 By Type - Global Rheumatic Heart Disease Treatment Revenue & Forecasts
  4.2.1 By Type - Global Rheumatic Heart Disease Treatment Revenue, 2017-2022
  4.2.2 By Type - Global Rheumatic Heart Disease Treatment Revenue, 2023-2028
  4.2.3 By Type - Global Rheumatic Heart Disease Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Rheumatic Heart Disease Treatment Market Size, 2021 & 2028
  5.1.2 Children
  5.1.3 Adult
5.2 By Application - Global Rheumatic Heart Disease Treatment Revenue & Forecasts
  5.2.1 By Application - Global Rheumatic Heart Disease Treatment Revenue, 2017-2022
  5.2.2 By Application - Global Rheumatic Heart Disease Treatment Revenue, 2023-2028
  5.2.3 By Application - Global Rheumatic Heart Disease Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Rheumatic Heart Disease Treatment Market Size, 2021 & 2028
6.2 By Region - Global Rheumatic Heart Disease Treatment Revenue & Forecasts
  6.2.1 By Region - Global Rheumatic Heart Disease Treatment Revenue, 2017-2022
  6.2.2 By Region - Global Rheumatic Heart Disease Treatment Revenue, 2023-2028
  6.2.3 By Region - Global Rheumatic Heart Disease Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Rheumatic Heart Disease Treatment Revenue, 2017-2028
  6.3.2 US Rheumatic Heart Disease Treatment Market Size, 2017-2028
  6.3.3 Canada Rheumatic Heart Disease Treatment Market Size, 2017-2028
  6.3.4 Mexico Rheumatic Heart Disease Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Rheumatic Heart Disease Treatment Revenue, 2017-2028
  6.4.2 Germany Rheumatic Heart Disease Treatment Market Size, 2017-2028
  6.4.3 France Rheumatic Heart Disease Treatment Market Size, 2017-2028
  6.4.4 U.K. Rheumatic Heart Disease Treatment Market Size, 2017-2028
  6.4.5 Italy Rheumatic Heart Disease Treatment Market Size, 2017-2028
  6.4.6 Russia Rheumatic Heart Disease Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries Rheumatic Heart Disease Treatment Market Size, 2017-2028
  6.4.8 Benelux Rheumatic Heart Disease Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Rheumatic Heart Disease Treatment Revenue, 2017-2028
  6.5.2 China Rheumatic Heart Disease Treatment Market Size, 2017-2028
  6.5.3 Japan Rheumatic Heart Disease Treatment Market Size, 2017-2028
  6.5.4 South Korea Rheumatic Heart Disease Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia Rheumatic Heart Disease Treatment Market Size, 2017-2028
  6.5.6 India Rheumatic Heart Disease Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Rheumatic Heart Disease Treatment Revenue, 2017-2028
  6.6.2 Brazil Rheumatic Heart Disease Treatment Market Size, 2017-2028
  6.6.3 Argentina Rheumatic Heart Disease Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Rheumatic Heart Disease Treatment Revenue, 2017-2028
  6.7.2 Turkey Rheumatic Heart Disease Treatment Market Size, 2017-2028
  6.7.3 Israel Rheumatic Heart Disease Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia Rheumatic Heart Disease Treatment Market Size, 2017-2028
  6.7.5 UAE Rheumatic Heart Disease Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Eli Lilly
  7.1.1 Eli Lilly Corporate Summary
  7.1.2 Eli Lilly Business Overview
  7.1.3 Eli Lilly Rheumatic Heart Disease Treatment Major Product Offerings
  7.1.4 Eli Lilly Rheumatic Heart Disease Treatment Revenue in Global Market (2017-2022)
  7.1.5 Eli Lilly Key News
7.2 GlaxoSmithKline
  7.2.1 GlaxoSmithKline Corporate Summary
  7.2.2 GlaxoSmithKline Business Overview
  7.2.3 GlaxoSmithKline Rheumatic Heart Disease Treatment Major Product Offerings
  7.2.4 GlaxoSmithKline Rheumatic Heart Disease Treatment Revenue in Global Market (2017-2022)
  7.2.5 GlaxoSmithKline Key News
7.3 Sanofi
  7.3.1 Sanofi Corporate Summary
  7.3.2 Sanofi Business Overview
  7.3.3 Sanofi Rheumatic Heart Disease Treatment Major Product Offerings
  7.3.4 Sanofi Rheumatic Heart Disease Treatment Revenue in Global Market (2017-2022)
  7.3.5 Sanofi Key News
7.4 Bristol-Myers Squibb
  7.4.1 Bristol-Myers Squibb Corporate Summary
  7.4.2 Bristol-Myers Squibb Business Overview
  7.4.3 Bristol-Myers Squibb Rheumatic Heart Disease Treatment Major Product Offerings
  7.4.4 Bristol-Myers Squibb Rheumatic Heart Disease Treatment Revenue in Global Market (2017-2022)
  7.4.5 Bristol-Myers Squibb Key News
7.5 AstraZeneca
  7.5.1 AstraZeneca Corporate Summary
  7.5.2 AstraZeneca Business Overview
  7.5.3 AstraZeneca Rheumatic Heart Disease Treatment Major Product Offerings
  7.5.4 AstraZeneca Rheumatic Heart Disease Treatment Revenue in Global Market (2017-2022)
  7.5.5 AstraZeneca Key News
7.6 AbbVie
  7.6.1 AbbVie Corporate Summary
  7.6.2 AbbVie Business Overview
  7.6.3 AbbVie Rheumatic Heart Disease Treatment Major Product Offerings
  7.6.4 AbbVie Rheumatic Heart Disease Treatment Revenue in Global Market (2017-2022)
  7.6.5 AbbVie Key News
7.7 Merck
  7.7.1 Merck Corporate Summary
  7.7.2 Merck Business Overview
  7.7.3 Merck Rheumatic Heart Disease Treatment Major Product Offerings
  7.7.4 Merck Rheumatic Heart Disease Treatment Revenue in Global Market (2017-2022)
  7.7.5 Merck Key News
7.8 Roche
  7.8.1 Roche Corporate Summary
  7.8.2 Roche Business Overview
  7.8.3 Roche Rheumatic Heart Disease Treatment Major Product Offerings
  7.8.4 Roche Rheumatic Heart Disease Treatment Revenue in Global Market (2017-2022)
  7.8.5 Roche Key News
7.9 Pfizer
  7.9.1 Pfizer Corporate Summary
  7.9.2 Pfizer Business Overview
  7.9.3 Pfizer Rheumatic Heart Disease Treatment Major Product Offerings
  7.9.4 Pfizer Rheumatic Heart Disease Treatment Revenue in Global Market (2017-2022)
  7.9.5 Pfizer Key News
7.10 Boehringer Ingelheim Pharma
  7.10.1 Boehringer Ingelheim Pharma Corporate Summary
  7.10.2 Boehringer Ingelheim Pharma Business Overview
  7.10.3 Boehringer Ingelheim Pharma Rheumatic Heart Disease Treatment Major Product Offerings
  7.10.4 Boehringer Ingelheim Pharma Rheumatic Heart Disease Treatment Revenue in Global Market (2017-2022)
  7.10.5 Boehringer Ingelheim Pharma Key News
7.11 Bayer
  7.11.1 Bayer Corporate Summary
  7.11.2 Bayer Business Overview
  7.11.3 Bayer Rheumatic Heart Disease Treatment Major Product Offerings
  7.11.4 Bayer Rheumatic Heart Disease Treatment Revenue in Global Market (2017-2022)
  7.11.5 Bayer Key News
7.12 Sun Pharm
  7.12.1 Sun Pharm Corporate Summary
  7.12.2 Sun Pharm Business Overview
  7.12.3 Sun Pharm Rheumatic Heart Disease Treatment Major Product Offerings
  7.12.4 Sun Pharm Rheumatic Heart Disease Treatment Revenue in Global Market (2017-2022)
  7.12.5 Sun Pharm Key News
7.13 Amneal Pharmaceuticalsd
  7.13.1 Amneal Pharmaceuticalsd Corporate Summary
  7.13.2 Amneal Pharmaceuticalsd Business Overview
  7.13.3 Amneal Pharmaceuticalsd Rheumatic Heart Disease Treatment Major Product Offerings
  7.13.4 Amneal Pharmaceuticalsd Rheumatic Heart Disease Treatment Revenue in Global Market (2017-2022)
  7.13.5 Amneal Pharmaceuticalsd Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Rheumatic Heart Disease Treatment Market Opportunities & Trends in Global Market
Table 2. Rheumatic Heart Disease Treatment Market Drivers in Global Market
Table 3. Rheumatic Heart Disease Treatment Market Restraints in Global Market
Table 4. Key Players of Rheumatic Heart Disease Treatment in Global Market
Table 5. Top Rheumatic Heart Disease Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Rheumatic Heart Disease Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Rheumatic Heart Disease Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Rheumatic Heart Disease Treatment Product Type
Table 9. List of Global Tier 1 Rheumatic Heart Disease Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Rheumatic Heart Disease Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Rheumatic Heart Disease Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Rheumatic Heart Disease Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Rheumatic Heart Disease Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Rheumatic Heart Disease Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Rheumatic Heart Disease Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Rheumatic Heart Disease Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Eli Lilly Corporate Summary
Table 31. Eli Lilly Rheumatic Heart Disease Treatment Product Offerings
Table 32. Eli Lilly Rheumatic Heart Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 33. GlaxoSmithKline Corporate Summary
Table 34. GlaxoSmithKline Rheumatic Heart Disease Treatment Product Offerings
Table 35. GlaxoSmithKline Rheumatic Heart Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Sanofi Corporate Summary
Table 37. Sanofi Rheumatic Heart Disease Treatment Product Offerings
Table 38. Sanofi Rheumatic Heart Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Bristol-Myers Squibb Corporate Summary
Table 40. Bristol-Myers Squibb Rheumatic Heart Disease Treatment Product Offerings
Table 41. Bristol-Myers Squibb Rheumatic Heart Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 42. AstraZeneca Corporate Summary
Table 43. AstraZeneca Rheumatic Heart Disease Treatment Product Offerings
Table 44. AstraZeneca Rheumatic Heart Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 45. AbbVie Corporate Summary
Table 46. AbbVie Rheumatic Heart Disease Treatment Product Offerings
Table 47. AbbVie Rheumatic Heart Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Merck Corporate Summary
Table 49. Merck Rheumatic Heart Disease Treatment Product Offerings
Table 50. Merck Rheumatic Heart Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Roche Corporate Summary
Table 52. Roche Rheumatic Heart Disease Treatment Product Offerings
Table 53. Roche Rheumatic Heart Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Pfizer Corporate Summary
Table 55. Pfizer Rheumatic Heart Disease Treatment Product Offerings
Table 56. Pfizer Rheumatic Heart Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 57. Boehringer Ingelheim Pharma Corporate Summary
Table 58. Boehringer Ingelheim Pharma Rheumatic Heart Disease Treatment Product Offerings
Table 59. Boehringer Ingelheim Pharma Rheumatic Heart Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 60. Bayer Corporate Summary
Table 61. Bayer Rheumatic Heart Disease Treatment Product Offerings
Table 62. Bayer Rheumatic Heart Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 63. Sun Pharm Corporate Summary
Table 64. Sun Pharm Rheumatic Heart Disease Treatment Product Offerings
Table 65. Sun Pharm Rheumatic Heart Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 66. Amneal Pharmaceuticalsd Corporate Summary
Table 67. Amneal Pharmaceuticalsd Rheumatic Heart Disease Treatment Product Offerings
Table 68. Amneal Pharmaceuticalsd Rheumatic Heart Disease Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Rheumatic Heart Disease Treatment Segment by Type in 2021
Figure 2. Rheumatic Heart Disease Treatment Segment by Application in 2021
Figure 3. Global Rheumatic Heart Disease Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Rheumatic Heart Disease Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Rheumatic Heart Disease Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Rheumatic Heart Disease Treatment Revenue in 2021
Figure 8. By Type - Global Rheumatic Heart Disease Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Rheumatic Heart Disease Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Rheumatic Heart Disease Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Rheumatic Heart Disease Treatment Revenue Market Share, 2017-2028
Figure 12. US Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Rheumatic Heart Disease Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Rheumatic Heart Disease Treatment Revenue Market Share, 2017-2028
Figure 24. China Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Rheumatic Heart Disease Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Rheumatic Heart Disease Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Rheumatic Heart Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Eli Lilly Rheumatic Heart Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. GlaxoSmithKline Rheumatic Heart Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Sanofi Rheumatic Heart Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Bristol-Myers Squibb Rheumatic Heart Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. AstraZeneca Rheumatic Heart Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. AbbVie Rheumatic Heart Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Merck Rheumatic Heart Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Roche Rheumatic Heart Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Pfizer Rheumatic Heart Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Boehringer Ingelheim Pharma Rheumatic Heart Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Bayer Rheumatic Heart Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Sun Pharm Rheumatic Heart Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Amneal Pharmaceuticalsd Rheumatic Heart Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)